Articles by American Association for Cancer Research

More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has not benefited all patients

AI-powered, multilingual cancer research pipeline will accelerate the pace of global data curation and expand access to real-world clinical data

Certain cancer patients in US states that expanded Medicaid experienced increased survival, especially in rural and high-poverty regions

AACR applauds appointment of Anthony G. Letai, MD, PhD, as director of the National Cancer Institute

The FDA approved 20 new cancer drugs during the 12 months covered by the report, but turmoil at NIH threatens continued progress

Some 89 percent of voters support the federal government using taxpayer dollars to fund medical research

In a statement, the American Association for Cancer Research emphasizes the critical role of sustained federal investment in advancing diagnostics, treatments, and equitable access to care for all cancer patients

The FY2026 budget proposal includes devastating cuts to NIH of $18 billion, which would result in a nearly 40 percent cut in NIH’s budget for lifesaving research

The AACR Trailblazer Cancer Research Grant Program will award $15 million over three years

New article outlines best practices, novel statistical methods, and suggestions for improving benefit-risk assessments in clinical trials

Saruparib has higher selectivity for PARP1, improving safety and tolerability compared to existing first-gen PARP inhibitors

When combined with CA 19-9, the novel biopsy accurately detected 97 percent of stage 1–2 pancreatic cancers

The HER2CLIMB-02 trial reveals significant benefits, especially for breast cancer patients with brain metastases

Vaccination given in combination with autologous stem cell transplant was associated with long-term disease control

Current guidelines ruled 60 percent of individuals identified with HBOC risk as ineligible for genetic testing